Jefferies analyst Wei Sim upgraded Pro Medicus (PMCUF) to Buy from Hold with a A$155 price target With over 90% recurring revenue and a capital-light model, the firm remains confident in Pro Medicus’ ability to deliver sustainable revenue and margin growth, the analyst tells investors amid a broader healthcare IT sector de-rating.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMCUF:
- Pro Medicus Sets Date for HY26 Results and Investor Webcast
- Pro Medicus Issues 47,930 Unquoted Performance Rights Under Employee Incentive Scheme
- Pro Medicus Announces Lapse of 3,134 Performance Rights
- Pro Medicus to Issue 27,986 Unquoted Performance Rights Under Incentive Scheme
- Pro Medicus Issues 40,358 Unquoted Performance Rights Under Staff Incentive Plan